» Articles » PMID: 37937105

Evaluation of the Effects of the Pandemic Period on Cirrhosis Patients

Overview
Publisher Termedia
Specialty Gastroenterology
Date 2023 Nov 8
PMID 37937105
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Cirrhosis is a common liver disease, which is characterized by life-limiting complications. In cirrhosis, liver ACE2 mRNA levels were 34-times upregulated, ACE2 protein 97-times upregulated, and ACE2 receptors increased in 80% of hepatocytes. Increased ACE2 receptor sensitizes hepatocytes to COVID-19.

Aim: To evaluate the applications of cirrhosis patients to the Emergency Department before and after the pandemic.

Material And Methods: The study was conducted retrospectively in a single centre on cirrhotic patients who applied to the Emergency Department in a 2-year period. The obtained data were compared with the laboratory values of the patients: the severity of cirrhosis, the reasons for applying to the Emergency Department, hospitalization/discharge status, and pre-pandemic and pandemic period values. The mortality of the patients was recorded.

Results: The biochemical values, CTP score, and complications of cirrhosis patients deteriorated during the pandemic period, which contributed to the increase in mortality and that the CTP score and its complications worsened, which contributed to the increase in mortality. COVID-19 positivity contributes to the progression of the CTP score, but it is not directly associated with mortality.

Conclusions: We think that new treatment protocols should be included in the guidelines to minimize the effects of this type of viral infection on the liver.

References
1.
An Y, Ma Z, Guo X, Tang Y, Meng H, Yu H . Comparison of liver biochemical abnormality between COVID-19 patients with liver cirrhosis versus COVID-19 alone and liver cirrhosis alone: A STROBE observational study. Medicine (Baltimore). 2021; 100(19):e25497. PMC: 8133226. DOI: 10.1097/MD.0000000000025497. View

2.
Simpson S, Kay F, Abbara S, Bhalla S, Chung J, Chung M . Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA - Secondary Publication. J Thorac Imaging. 2020; 35(4):219-227. PMC: 7255403. DOI: 10.1097/RTI.0000000000000524. View

3.
Nusrat S, Khan M, Fazili J, Madhoun M . Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014; 20(18):5442-60. PMC: 4017060. DOI: 10.3748/wjg.v20.i18.5442. View

4.
Tapper E, Asrani S . The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020; 73(2):441-445. PMC: 7194911. DOI: 10.1016/j.jhep.2020.04.005. View

5.
Bajaj J, Garcia-Tsao G, Biggins S, Kamath P, Wong F, McGeorge S . Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2020; 70(3):531-536. PMC: 7371484. DOI: 10.1136/gutjnl-2020-322118. View